Dexmedetomidine Enhances Adenosine Diphosphate-Induced Platelet Aggregation and Activation

• Main Authors: Pai-Ching Huang, 黃百慶
• Other Authors: 李繼源
• Format: Others
• Language: zh-TW
• Published: 2012
• Online Access: http://ndltd.ncl.edu.tw/handle/77082214881544956058

碩士 === 中國醫藥大學 === 臨床醫學研究所碩士班 === 100 === As an integral part in hemostasis, platelet has also been proved to play an important role in inflammation. Platelet activation was the very first step to participate in either hemostasis or inflammation. Many factors or molecules have been demonstrated as platelet stimulants. More and more platelet receptors were then discovered as well. The complicated networks of these receptor functions were composed of several distinct pathways. We could measure the different chemical products or physical phenomenons and thereby study the possible pathways in which were involved. In Taiwan, Precedex (dexmedetomidine) was used, as a sedative agent with analgesic effect, more and more frequently in ICU and operating room. In this study, we were the first to described that dexmedetomidine might have pro-aggregatory effect on platelet in vitro. We used several indicators of platelet activation, such as platelet aggregation, P-selectin, platelet-leukocyte aggregate, [Ca2+]i, and ATP, to measure the effect of dexmedetomidine on ADP-induced platelet aggregation and activation. Moreover, we used alpha antagonists to prove the above effect was through the activation of alpha-2 receptor on platelets. Then we compared the platelet counts before and after use of dexmedetomidine on ICU patients to preliminarily find out it’s possible effects in vivo. In this series of experiments, we have proved that dexmedetomidine could enhance ADP-induced platelet activation and aggregation through alpha-2 receptor in vitro. We should be cautious about prescribing dexmedetomidine for the patients with high risk of thromboembolism or inflammatory diseases.